140 research outputs found
Antiangiogenic and antiapoptotic treatment in advanced melanoma
Melanoma is one of the most aggressive forms of skin cancer. Currently
available treatments have little overall impact on survival rates of
patients with advanced melanoma. Advances in the understanding of the
molecular pathways related to tumor growth and metastatic spread have
resulted in the development of targeted therapies designed to act on
specific genes or molecules of these pathways. Newly introduced agents
that target the process of angiogenesis or inhibit antiapoptotic
proteins have been investigated in melanoma. Although the use of these
agents as monotherapy has yielded disappointing results, their impact on
survival when combined with cytotoxic chemotherapy agents is currently
under investigation. Larger phase III trials are needed to clarify the
optimal clinical benefit that can be expected of this class of agents.
(C) 2013 Elsevier Inc. All rights reserved
Evolving Treatment Landscape of <i>HER2</i>-mutant Non-Small Cell Lung Cancer: Trastuzumab Deruxtecan and Beyond
Successful targeting of HER2-activating mutations in DESTINY-Lung02 phase II study has led to the approval of the antibody–drug conjugate (ADC) trastuzumab deruxtecan (T-DXd) as second-line treatment in patients with non-small cell lung cancer (NSCLC). Despite the impressive results, several matters need to be addressed, including the clinical activity of T-DXd in patients with disease in the central nervous system as well as the role of T-DXd in the context of HER2 overexpression. Additionally, data regarding novel agents used to target HER2 continue to accumulate. This review highlights the challenges and unanswered questions that have emerged after the approval of T-DXd in patients with HER2-mutant NSCLC
Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer: An analytical database
Background: After the discovery of somatic mutations in the tyrosine
kinase domain (exons 18-24) of the epidermal growth factor receptor
(EGFR) correlating with responses of non-srnall cell lung cancer (NSCLC)
to the tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib, there
has been increasing interest in utilizing this molecular marker for
treatment selection. We aimed to analytically catalogue the Mutational
spectrum of somatic Mutations in EGFR and format a database allowing
correlation of specific mutations with clinico-pathologic factors and
response to TKIs.
Methods: A computerized search of MEDLINE (January I 2004 to,June 30,
2007) was performed to identify articles reporting on NSCLC patients
harboring somatic mutations in EGFR. Demographic, clinico-pathologic,
Mutational, and response data were extracted and tabulated.
Results: A total of 202 eligible articles were identified. We report
data on 12,244 patients with 3381 somatic EGFR mutations. The majority
Of mutations have been reported on only one occasion (158 of 254,
62.2%), and only nine Mutations occur at a rate of L858R and
delE746-A750 account for 32.84% and 24.28% of all mutations,
respectively; with 50% of mutations being exon 19 deletions or
“deletional-insertions.” There is a clear association between the
presence of Mutations and response to TKI.
Conclusions: We have generated a free access, nonprofit online
analytical database of somatic EGFR mutations in NSCLC. Cumulative
information will be made available through a routine update of both
database tables and associated graphical representations. Direct updates
and Submissions through the online site (www.somaticmutations-EGFR.org)
are encouraged, as are comments and suggestions
Therapeutic Effect of mRNA SARS-CoV-2 Vaccine on Melanoma Skin Metastases
A unique case of multiple metastatic melanoma skin nodules regression in a heavily pretreated, 72-year-old Caucasian female, after administering the second dose of the SARS-CoV-2 mRNA Pfizer-BioNTech vaccine, is presented. Two days after vaccination, all her melanoma skin nodules became painful and were significantly reduced in size. Physical examination and ultrasound imaging confirmed the patient’s observation. The effect was sustained, and further reduction of the nodules occurred after the third vaccine dose. One of the reduced nodules was removed, histologically examined, and its histopathology was compared to that of another such nodule removed and examined earlier. Distinct differences were observed between the two histopathologies, with the most notable the unexpected finding of the absence of infiltrating lymphocytes in the reducer nodule’s melanoma tissue. Based on this observation, the possible immunological mechanism(s) leading to the vaccine’s effect are speculated. More possible is the vaccine’s antitumor and apoptotic activity via stimulation of the Tol Like Receptors 3, 7, and 8, and (downstream) the nuclear factor kappa-light-chain-enhancer of the activated B cells pathway of the non-lymphocytic immune effector cells
- …